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Effects of high CD4 cell counts on 
death and attrition among HIV 
patients receiving antiretroviral 
treatment: an observational cohort 
study
Zhenzhu Tang1, Stephen W. Pan2, Yuhua Ruan1,3, Xuanhua Liu1, Jinming Su1, Qiuying Zhu1, 
Zhiyong Shen1, Heng Zhang3, Yi Chen1, Guanghua Lan1, Hui Xing3, Lingjie Liao3, Yi Feng3 & 
Yiming Shao1,3
Current WHO guidelines recommend initiating ART regardless of CD4+ cell count. In response, we 
conducted an observational cohort study to assess the effects of pre-ART CD4+ cell count levels on 
death, attrition, and death or attrition in HIV treated patients. This large HIV treatment cohort study 
(n = 49,155) from 2010 to 2015 was conducted in Guangxi, China. We used a Cox regression model to 
analyze associations between pre-ART CD4+ cell counts and death, attrition, and death or attrition. 
The average mortality and ART attrition rates among all treated patients were 2.63 deaths and 5.32 
attritions per 100 person-years, respectively. Compared to HIV patients with <350 CD4+ cells/mm3 
at ART initiation, HIV patients with >500 CD4+ cells/mm3 at ART initiation had a significantly lower 
mortality rate (Adjusted hazard ratio: 0.56, 95% CI: 0.40–0.79), but significantly higher ART attrition 
rate (AHR: 1.17, 95% CI: 1.03–1.33). Results from this study suggest that HIV patients with high CD4+ 
cell counts at the time of ART initiation may be at greater risk of treatment attrition. To further reduce 
ART attrition, it is imperative that patient education and healthcare provider training on ART adherence 
be enhanced and account for CD4 levels at ART initiation.
Since its development in 1996, highly active antiretroviral therapy (HAART) has been shown to rejuvenate 
the immune system of HIV infected individuals, prevent onset of opportunistic infections that often lead to 
death among HIV patients, and generally improve the quality of life among HIV infected persons worldwide1–4. 
Moreover, successful ART has had significant effects on viral suppression and reducing transmission from part-
ner to partner. Recently, a randomized clinical trial and a several observational studies showed that ART can 
significantly reduce transmissions in serodiscordant heterosexual couples5–10. Due to its impact on immunocom-
petence and HIV transmission, HAART has led to significant declines in AIDS-related morbidity and premature 
mortality.
Research in recent years has indicated that early initiation of ART can delay time to AIDS-related events and 
decrease incidences of morbidity and mortality, and high current CD4+ T cell count can be associated with 
suboptimal adherence to ART11–17. Given the clinical benefits and significant reductions in HIV transmission 
associated with early ART initiation, the World Health Organization (WHO) revised their ART guidelines in 
2010 by increasing the threshold for ART eligibility in developed countries from <200 CD4+ cells/ mm3 to <350 
CD4+ cells/ mm3 18, 19. In an effort to end the HIV epidemic by 2030, ART guidelines were again revised in 2015, 
whereby all people living with HIV were recommended for ART, regardless of WHO clinical stage or CD4 cell 
count20. Implementation of these new guidelines will provide a critical contribution to achieving the UNAIDS’ 
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“90-90-90” target: 90% of all people living with HIV diagnosed, 90% of all people diagnosed with HIV receiving 
cART, and 90% of all people receiving cART virally suppressed20, 21. However, despite recommendations to initiate 
ART at any CD4 cell count, there exists limited understanding about mortality, attrition, and primary treatment 
outcomes among HIV patients with ≥500 CD4+ cells/mm3over long-durations of ART in real-world settings.
In China, HIV-related mortality has significantly declined since the National Free Antiretroviral Treatment 
Program (NFATP) was initiated in 2002 and rapidly scaled up22–26. Following updated WHO ART guidelines in 
2010, China further expanded ART services in order to reduce overall mortality among HIV infected patients, 
prevent transmission among key populations, and provide ART to those with higher CD4 counts7, 10, 26. By the 
end of 2015, more than 382,139 patients had received ART treatment27. Today, China aims to achieve significant 
reductions in HIV incidence and HIV-related mortality by adopting the UNAIDS 90–90–90 policy.
In Southwest China, the Guangxi Zhuang Autonomous Region accounts for 10% of all reported HIV cases 
nationwide28, and is critical in the country’s HIV prevention and treatment campaign. Situated in the middle 
of major heroin trafficking routes that begin in Southeast Asia and Southwest China, and continue on towards 
Guangdong and Hong Kong29, 30, injection drug use was the main mode of HIV transmission in the earlier years 
of the epidemic. However, by the end of 2015, sexual transmission had become the dominant mode of transmis-
sion, with heterosexual transmission accounting for 92% of reported HIV cases in Guangxi28. Based on a large 
ART treatment database from Guangxi, we conducted an observational cohort study in order to examine the 
effects of high CD4+ cell counts (≥500 cells/mm3) on treatment outcomes among HIV infected patients receiv-
ing ART in a real-world setting.
Results
General characteristics of study population. A total of 49309 HIV patients initiated ART between 2010 
and 2015 in Guangxi,China, 125 of whom were less than 18 years old, and 29 of whom had no follow-up data. 
Thus, 49155 eligible study participants were included in this prospective follow-up study. Table 1 presents gen-
eral characteristics of HIV patients. Patients over 40 years old represented 59.9% of all study participants. The 
percentage of males was 67.1%, and 68.7% of HIV participants were married. The main route of HIV infection 
was heterosexual intercourse (88.4%), followed by injection drug use (7.3%), homosexual intercourse (2.1%), 
and other routes of transmission (2.2%). Prior to ART initiation, patients with CD4+ counts <350 cells/mm3, 
350–499 cells/mm3, and ≥500 cells/mm3 accounted for 84.5%, 10.0% and 3.7% of all patients, respectively. Those 
classified as WHO clinic stage III/IV before ART represented 41.2% of all patients. The percentage of patients 
who initiated ART with first-line ART and second-line ART was 90.3% and 9.7%, respectively. First-line ART 
constituted 84.5% of current regimens.
Mortality rates. Among all eligible HIV infected patients who initiated ART between 2010 and 2015 in 
Guangxi, China, 3411 deaths were observed, 4507 patients lost to follow-up, and 2396 patients stopped ART. Of 
the 2396 patients who stopped ART, 1358 (56.7%) were due to poor adherence, 437 (18.2%) were due to drug side 
effects, 70 (2.9%) were due to economic issues, and 531(22.2%) were due to other reasons. The average mortality 
rate was 2.63 deaths per 100 person-years among all patients (Table 2).
Attrition rates. Among all eligible HIV infected patients who initiated ART between 2010 and 2015 in 
Guangxi, China, 6903 attritions were observed. Of 6903 patient attritions, 4507 patients were lost to follow-up, 
and 2396 patients stopped ART. The average attrition rate was 5.32 attritions per 100 person-years among all 
treated patients (Table 3).
Death + attrition rates. Among all eligible HIV infected patients who initiated ART between 2010 and 
2015 in Guangxi, China, 10314 death + attritions were observed. The average death + attrition rate was 7.94 per 
100 person-years among all treated patients (Table 4).
Effects of pre-ART CD4 count on death. Table 5 presents the unadjusted and adjusted effects of pre-ART 
CD4 counts on death after ART initiation. In the adjusted models, 350–499 CD4 cells/mm3 before ART (com-
pared to <350 cells/mm3 before ART, AHR = 0.45, 95% CI: 0.36–0.56) and ≥500 CD4 cells/mm3 before ART 
(compared to <350 cells/mm3 before ART, AHR = 0.56, 95% CI: 0.40–0.79) were both inversely significantly 
associated with death in HIV patients who started ART. Similar effects of pre-ART CD4 counts on death after 
ART initiation were observed even after excluding individuals with missing baseline CD4 counts (Supplementary 
Table 2).
Effects of pre-ART CD4 count on attrition. Table 6 presents the unadjusted and adjusted effects of 
pre-ART CD4+ count on attrition after ART initiation. Compared to having <350 CD4 cells/mm3 pre-ART 
initiation, having 350–499 CD4 cells/mm3 at pre-ART initiation was marginally significantly associated with 
attrition (adjusted hazard ratio (AHR = 1.08, 95% CI: 0.99–1.17), and having ≥500 CD4 cells/mm3 at pre-ART 
initiation was significantly associated with attrition (AHR = 1.17, 95% CI: 1.03–1.33). Similar effects of pre-ART 
CD4 counts on attrition after ART initiation were observed even after excluding individuals with missing baseline 
CD4 counts (Supplementary Table 3).
Effects of pre-ART CD4 count on death + attrition. Table 7 presents the unadjusted and adjusted 
effects of pre-ART CD4+ count on death + attrition after ART initiation. Compared to having <350 CD4+ 
cells/mm3 pre-ART initiation, neither having 350–499 CD4+ cells/mm3 at pre-ART initiation nor having ≥ 500 
CD4+ cells/mm3 at pre-ART initiation was significantly associated with death + attrition (AHR = 0.94, 95% 
CI: 0.87–1.01 and AHR = 1.04, 95% CI: 0.93–1.18, respectively). Similar effects of pre-ART CD4 counts on 
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death + attrition after ART initiation were observed even after excluding individuals with missing baseline CD4 
counts (Supplementary Table 4).
Effects of CD4 count before ART on loss to follow-up and medication cessation. We conducted 
a separate analysis for loss to follow-up and medication cessation as the outcomes of interest (Supplementary 
Tables 6–9). Generally, the effect of ≥500 CD4 cells/mm3 at pre-ART baseline on attrition was similar to its effects 
on loss to follow-up and medication cessation.
Variable Number %
Total 49155 100.0
Age (years)
  <40 19728 40.1
  ≥40 29427 59.9
Sex
  Male 32977 67.1
  Female 16178 32.9
Marital status
  Married 33778 68.7
  Other 15377 31.3
Route of HIV infection
  Heterosexual intercourse 43441 88.4
  Homosexual intercourse 1021 2.1
  Injection drug use 3603 7.3
  Other 1090 2.2
CD4 count before ART (cells/mm3)
  <350 41554 84.5
  350–499 4921 10.0
  ≥500 1796 3.7
  Missing 884 1.8
WHO clinic stage before ART
  I/II 28919 58.8
  III/IV 20236 41.2
Initial ART regimen
  The first-line ART 44388 90.3
  The second-line ART 4767 9.7
Current ART regimen
  The first-line ART 41558 84.5
  The second-line ART 7597 15.5
Year of ART initiation
  2010 5710 11.6
  2011 7743 15.8
  2012 9210 18.7
  2013 8850 18.0
  2014 9440 19.2
  2015 8202 16.7
Table 1. Characteristics of HIV patients who initiated ART between 2010 and 2015 in Guangxi, China.
Variable Number of HIV patients Deaths Person years Deaths/100 person year (95% CI)
Overall 49155 3411 129837.65 2.63(2.54–2.72)
0 to 1 year 49155 2066 44361.04 4.66(4.46–4.86)
0 to 2 year 49155 2719 77506.09 3.51(3.38–3.64)
0 to 3 year 49155 3080 101464.68 3.04(2.93–3.14)
0 to 4 year 49155 3298 117556.62 2.81(2.71–2.90)
0 to 5 year 49155 3382 126356.97 2.68(2.59–2.77)
0 to 6 year 49155 3411 129837.65 2.63(2.54–2.72)
Table 2. Mortality rates in HIV-infected patients who started ART between 2010 and 2015 in Guangxi, China, 
by year post-ART initiation.
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Discussion
Although the “90-90-90” targets and corresponding HIV treatment guidelines have already been endorsed by 
UNAIDS20, additional high quality evidence is needed to better understand death and attrition rates among those 
who initiate ART with pre-ART ≥500 CD4+ cells/mm3. However, most relevant studies that have examined 
patient death and treatment attrition after ART initiation, have defined early treatment as initiating ART when 
CD4+ counts were ≥350 (cells/mm3)11–13, 15–17. To better understand the effects of high CD4+ cell counts (≥500 
Variable Number of HIV patients Attritions Person years Attritions/100 person year (95% CI)
Overall 49155 6903 129837.65 5.32(5.19–5.44)
0 to 1 year 49155 4178 44361.04 9.42(9.13–9.70)
0 to 2 year 49155 5515 77506.09 7.12(6.93–7.30)
0 to 3 year 49155 6244 101464.68 6.15(6.00–6.31)
0 to 4 year 49155 6612 117556.62 5.62(5.49–5.76)
0 to 5 year 49155 6823 126356.97 5.40(5.27–5.53)
0 to 6 year 49155 6903 129837.65 5.32(5.19–5.44)
Table 3. Attrition rates in HIV-infected patients who started ART between 2010 and 2015 in Guangxi, China, 
by year post-ART initiation.
Variable Number of HIV patients Death + attritions Person years Death + attritions/100 person year (95% CI)
Overall 49155 10314 129837.65 7.94(7.79–8.10)
0 to 1 year 49155 6244 44361.04 14.08(13.73–14.42)
0 to 2 year 49155 8234 77506.09 10.62(10.39–10.85)
0 to 3 year 49155 9324 101464.68 9.19(9.00–9.38)
0 to 4 year 49155 9910 117556.62 8.43(8.26–8.60)
0 to 5 year 49155 10205 126356.97 8.08(7.92–8.23)
0 to 6 year 49155 10314 129837.65 7.94(7.79–8.10)
Table 4. Dearth + attrition rates in HIV-infected patients who started ART between 2010 and 2015 in Guangxi, 
China, by year post-ART initiation.
Variable Number Deaths Person years
Deaths/100 person 
years (95% CI) HR (95% CI) P-value AHR* (95% CI) P-value
Total 49155 3411 129837.65 2.63(2.54–2.72)
CD4 count before ART (cells/mm3)
  <350 41554 3208 114372.74 2.80(2.71–2.90) 1.00 1.00
  350–499 4921 86 10118.95 0.85(0.67–1.03) 0.26(0.21–0.32) <0.01 0.45(0.36–0.56) <0.01
  ≥500 1796 36 3328.63 1.08(0.73–1.43) 0.31(0.22–0.43) <0.01 0.56(0.40–0.79) 0.001
  Missing 884 81 2017.31 4.02(3.14–4.89) 1.31(1.05–1.64) 0.016 1.57(1.26–1.95) <0.01
Table 5. Effects of CD4 count before ART on death in HIV-infected patients who started ART between 2010 
and 2015 in Guangxi, China. *HR = hazard ratio; AHR = adjusted hazard ratio; covariates of the adjusted model 
included: age, sex, marital status, route of HIV infection, WHO clinic stage before ART, initial ART regimen, 
year initiated ART.
Variable Number Attritions Person years
Attritions/100 person 
years (95% CI) HR (95% CI) P-value AHR* (95% CI) P-value
Total 49155 6903 129837.65 5.32(5.19–5.44)
CD4 count before ART (cells/mm3)
  <350 41554 5803 114372.74 5.07(4.94–5.20) 1.00 1.00
  350–499 4921 660 10118.95 6.52(6.02–7.02) 1.10(1.02–1.20) 0.016 1.08(0.99–1.17) 0.081
  ≥500 1796 254 3328.63 7.63(6.69–8.57) 1.23(1.08–1.39) 0.001 1.17(1.03–1.33) 0.019
  Missing 884 186 2017.31 9.22(7.90–10.55) 1.68(1.46–1.95) <0.01 1.61(1.39–1.86) <0.01
Table 6. Effects of CD4 count before ART on attrition in HIV-infected patients who started ART between 2010 
and 2015 in Guangxi, China. *HR = hazard ratio; AHR = adjusted hazard ratio; covariates of the adjusted model 
included: age, sex, marital status, route of HIV infection, WHO clinic stage before ART, initial ART regimen, 
year initiated ART.
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cells/mm3) on death and treatment attrition among HIV infected patients receiving ART in a real-world setting, 
we conducted a large observational cohort study among 49309 HIV+ patients receiving ART in rural Southwest 
China.
Our study found that the overall mortality rate was 2.63 per 100 person-years in HIV infected patients who 
started ART between 2010 and 2015 in Guangxi, China. Despite the achievements of China’s NFATP, this mortal-
ity rate remains much higher than that in developed countries2, 3. Continued improvement in the quality of HIV 
treatment and care is needed to further reduce the mortality rate in Chinese patients.
This large observational cohort study also showed that higher pre-ART CD4 cell counts (350–499 CD4+ cells/
mm3 and >500 CD4+ cells/mm3 versus <350 cells/mm3) were associated with lower mortality risk, confirming 
the results of previous studies11–13, 15–17. Such findings lend strong support to China’s adoption of the UNAIDs 
“90–90–90” policy, which includes continued expansion of HIV counseling and testing, and ART uptake by 90% 
of all people with diagnosed HIV infection20, 21.
The overall attrition rate among HIV patients in this study was 5.32 per 100 person-years, which is lower than 
that in other developing countries, but higher than that in developed countries31, 32. Compared with pre-ART 
CD4 counts <350 cells/mm3, attrition was marginally significantly associated with pre-ART CD4 counts 350–499 
cells/mm3, and significantly associated with pre-ART CD4 counts >500 cells/mm3. One major concern with initi-
ating cART among patients with a high CD4+ cell counts is increased risk of poor adherence. Given that patients 
with higher CD4+ cell counts are more likely to be AIDS asymptomatic, such individuals may be less willing or 
motivated to take cART33–36. High current CD4+ counts was strongly associated with lower adherence to ART, 
thus indicating that enhancement of adherence education is needed, especially for patients with high CD4+ 
counts17. In addition, attritions were associated with both individual and contextual factors, such as younger 
age, male gender, being single or divorced, poor adherence and drug side effects33. Given that retention in ART 
and care can help improve individual clinical outcomes, evaluating and optimizing HIV clinical care is essential 
for developing effective adherence interventions to reduce attrition. In China, TDF has replaced both stavudine 
(D4T) and zidovudine (AZT) given its more favorable toxicity profile, dosing, and cost-effectiveness37. It is imper-
ative for China to identify suitable timing to implement policies recommending initiation of ART regardless of 
CD4 cell counts. Rates of both death and attrition were highest among participants with missing CD4 count data, 
possibly due to a high proportion of individuals with WHO clinic stage III/IV before ART (31%) and possibly 
poor linkage to care. This study is arguably the first large, empirical study to suggest negative population-level 
consequences of initiating ART among HIV patients with pre-ART CD4+ counts ≥500 cells/mm3.
Our study has several limitations which warrant noting. First, although we controlled for numerous potential 
confounders in multivariable modeling, selection bias in the observational cohort study may have been an issue. 
As the study did not include individuals who were diagnosed with HIV but did not initiate ART, it is possible that 
individuals with poorer health-seeking behaviors were underrepresented in the study. Second, the median dura-
tion of follow-up was not very long. As time allows for longer-term studies of the new WHO treatment guidelines, 
future studies should consider using marginal structural models to evaluate the long-term effects of pre-ART 
CD4+ counts on treatment outcomes among HIV-infected patients receiving ART. Third, our study used 
all-cause mortality rather than HIV-related death, which arguably would have been more accurate for evaluating 
treatment effects. Fourth, this study was conducted in Guangxi, which only represents 13% of all HIV patients on 
ART in China28. Findings might not be fully representative of China. Fifth, parameter estimates may have been 
partially biased by the presence of unobserved time-varying confounders. Sixth, because lost to follow-up may 
have been associated with earlier time to death, mortality rate estimates may have been lower than the true rate.
To our knowledge, this is the first large-scale observational cohort study in a developing country to evaluate 
the effects of high CD4+ cell counts on treatment outcomes among HIV infected patients receiving ART. Novel 
results from this study provide compelling evidence for policy-makers to prioritize ART healthcare provider 
training, ART patient education, and the availability of simpler, more effective, safer and better tolerated reg-
imens, especially when initiating ART among HIV-infected patients with high CD4+ cell counts. Currently, 
China’s HIV treatment policies reflect the WHO and UNAIDS recommended guidelines to initiate treatment 
among all HIV patients regardless of CD4+ count, but further monitoring of treatment outcomes is needed to 
elucidate the determinants of long-term programmatic success.
Variable Number Death + attritions
Person 
years
Death + attritions 
/100 person years 
(95% CI) HR (95% CI) P-value AHR* (95% CI) P-value
Total 49155 10314 129837.65 7.94(7.79–8.10)
CD4 count before ART (cells/mm3)
  <350 41554 9011 114372.74 7.88(7.72–8.04) 1.00 1.00
  350–499 4921 746 10118.95 7.37(6.84–7.90) 0.80(0.74–0.86) <0.01 0.94(0.87–1.01) 0.105
  ≥500 1796 290 3328.63 8.71(7.71–9.72) 0.90(0.80–1.01) 0.077 1.04(0.93–1.18) 0.478
  Missing 884 267 2017.31 13.24(11.65–14.82) 1.55(1.37–1.75) <0.01 1.60(1.41–1.81) <0.01
Table 7. Effects of CD4 count before ART on Death + attritions in HIV-infected patients who started ART 
between 2010 and 2015 in Guangxi, China. *HR = hazard ratio; AHR = adjusted hazard ratio; covariates of the 
adjusted model included: age, sex, marital status, route of HIV infection, WHO clinic stage before ART, initial 
ART regimen, year initiated ART.
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Methods
Study design and study participants. This HIV ART observational cohort study was conducted in Guangxi, 
rural southwest China. Patients initiating free ART through the NFATP between January 1, 2010 and October 31, 2015 
were included. Patients who did not initiate ART during that time frame were not included in the study. Individuals 
who initiated free ART and were at least 18 years old at the time of ART initiation and provided informed consent were 
eligible to participate in the study. The Chinese national ART treatment criteria since 2010 was: (1) CD4 cell count 
<350/mm3; or (2) World Health Organization (WHO) stage III/IV clinic conditions; or (3) willingness to receive ART, 
regardless of the criteria 1 and 2, such as initiating ART at high CD4+ cell counts37. Currently, first-line ART regimens 
consist of [tenofovir (TDF) or azidothymidine (AZT)] + lamivudine (3TC) + [efavirenz (EFV) or nevirapine (NVP)]. 
Second-line ART regimens consist of TDF + 3TC + EFV/(LPV/r). By the end of 2015, more than 62,967 HIV patients 
had received ART in Guangxi, representing 13% of the total number of HIV patients on treatment in China28. This 
study and all methods were approved by the institutional review board (IRB) of the Guangxi Center for Disease Control 
and Prevention. All research methods in this study were carried out in accordance with the approved guidelines.
Data collection. Variables collected at baseline enrollment into the HIV ART observational cohort included: 
age, sex, ethnicity, marital status, route of HIV infection, CD4 count in the six months before ART, WHO clinic 
stage in the six months before ART, initial ART regimen, current ART regimen, and year of ART initiation. 
Variables collected at each follow-up included: transferals to another clinic, cessation of ART, loss to follow-up, 
duration of ART, and survival status. The follow up visits occurred at 0.5, 1, 2, and 3 months following ART ini-
tiation, and then every 3 months thereafter. Lost to follow-up was defined as missing more than 90 days after the 
last date seen in clinic, which was also defined as the date of withdrawal.
Statistical analysis. We conducted a prospective cohort analysis using Guangxi data from the NFATP. 
Treatment outcomes included death and attrition. Attrition was defined as cessation of ART or lost to follow-up 
as reported through the NFATP database. Time zero was defined as the date of ART initiation, and data were 
censored at April 30, 2016. Incidence rates were calculated based on Poisson distributions. Death, attrition, and 
death or attrition (death + attrition) incidence rates and their 95% confidence intervals (CI) were analyzed with 
incidence densities per 100 person-years of follow-up.
Cause-specific Cox proportional hazard models38 were used to evaluate effects of CD4+ count levels before 
ART on death, attrition, and death + attrition. Competing risks for cause-specific hazard models were censored 
accordingly. In order to control for potential confounding, the following baseline covariates of the adjusted model 
were included: age, sex, ethnicity, marital status, route of HIV infection, WHO clinic stage before ART, initial 
ART regimen, and year initiated ART. A two-sided p-value of 0.05 or less was regarded as statistically significant. 
Statistical Analysis System (SAS 9.1TM for Windows; SAS Institute Inc., NC, USA) was used for all the analyses.
Management of missing baseline CD4 data. A sensitivity analysis was conducted to assess for potential 
bias resulting from the 1.8% of individuals with missing baseline CD4 data, the only covariate with any missing 
data. First, we compared baseline demographics and treatment variables for complete cases (n = 48,271) and 
cases with missing baseline CD4 data (n = 884) (Supplementary Table 1). Results showed that demographics 
were similar between complete and missing cases, although cases with missing CD4 data appeared slightly less 
likely to be diagnosed as WHO clinic stage III/IV, compared to complete cases overall (31.4% vs 41.3%). Then, we 
re-analyzed the data using a complete-case analysis approach, whereby individuals with missing CD4 data were 
excluded from analysis (Supplementary Tables 2–4). Results of the sensitivity analysis indicated that effects of 
pre-ART CD4 counts on death, attrition, and death + attrition, were not meaningfully influenced by inclusion or 
exclusion of individuals with missing baseline CD4 data.
We also examined the proportion of individuals diagnosed as WHO clinic stage III/IV, stratified by baseline 
CD4 count in order to draw inferences about baseline CD4 counts among individuals with missing baseline CD4 
data (Supplementary Table 5). Results showed that individuals with missing baseline CD4 data were four times 
more likely to be diagnosed as WHO clinic stage III/IV, compared to individuals with baseline CD4 counts greater 
than 500 cells/mm3 (31.5% vs 8.1%). Given that 46.8% of individuals with baseline CD4 counts <350 cells/mm3 
were diagnosed as WHO clinic stage II/IV and assuming moderate to strong correlation between WHO clinical 
staging and baseline CD4 counts, these results suggest that the majority of individuals with missing baseline CD4 
counts had actual CD4 counts below 350 cells/mm3.
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